SPPL2a and SPPL2b promote intramembrane proteolysis of TNFα in activated dendritic cells to trigger IL-12 production

Nature Cell Biology

Volumn 8, Issue 8, 2006, Pages 843-848

  Friedmann, Elena ^a   Hauben, Ehud ^b   Maylandt, Kerstin ^c   Schleeger, Simone ^c   Vreugde, Sarah ^d   Lichtenthaler, Stefan F ^e   Kuhn, Peer Hendrik ^e   Stauffer, Daniela ^c   Rovelli, Giorgio ^c   Martoglio, Bruno ^c  

^a ETH ZURICH   (Switzerland)

^b SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^c NOVARTIS PHARMA AG   (Switzerland)

^d DIBIT   (Italy)

^e UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; SIGNAL PEPTIDASE II; SIGNAL PEPTIDASE IIA; SIGNAL PEPTIDASE IIB; SIGNAL PEPTIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELL ACTIVATION; CELL CULTURE; CELL MEMBRANE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; ENDOSOME; ENZYME ACTIVITY; ENZYME MECHANISM; HELA CELL; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOREGULATION; INNATE IMMUNITY; NORMAL HUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA ISOLATION; WESTERN BLOTTING;

EID: 33746618450     PISSN: 14657392     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncb1440     Document Type: Article

References (34)

1. Brown, M. S., Ye, J., Rawson, R. B. & Goldstein, J. L. Regulated intramembrane proteolysis: A control mechanism conserved from bacteria to humans. Cell 100, 391-398 (2000).
2. Rawson, R. B. Regulated intramembrane proteolysis: From the endoplasmic reticulum to the nucleus. Essays Biochem. 38, 155-168 (2002).
3. Brunkan, A. L. & Goate, A. M. Presenilin function and γ-secretase activity. J. Neurochem. 93, 769-792 (2005).
4. Weihofen, A. & Martoglio, B. Intramembrane-cleaving proteases: controlled liberation of proteins and bioactive peptides. Trends Cell Biol. 13, 71-78 (2003).
5. Haass, C. & Steiner, H. Alzheimer disease γ-secretase: A complex story of GxGD-type presenilin proteases. Trends Cell Biol. 12, 556-562 (2002).
6. Rawson, R. B. et al. Complementation cloning of S2P, a gene encoding a putative metalloprotease required for intramembrane cleavage of SREBPs. Mol. Cell 1, 47-57 (1997).
7. Ye, J. et al. ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs. Mol. Cell 6, 1355-1364 (2000).
8. Eissner, G., Kolch, W. & Scheurich, P. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev. 15, 353-366 (2004).
9. Laudon, H. et al. A nine-transmembrane domain topology for presenilin 1. J. Biol. Chem. 280, 35352-35360 (2005).
10. Martoglio, B. & Golde, T. E. Intramembrane-cleaving aspartic proteases and disease: Presenilins, signal peptide peptidase and their homologs. Hum. Mol. Genet. 12, R201-R206 (2003).
11. Friedmann, E. et al. Consensus analysis of signal peptide peptidase and homologous human aspartic proteases reveals opposite topology of catalytic domains compared with presenilins. J. Biol. Chem. 279, 50790-50798 (2004).
12. Weihofen, A., Binns, K., Lemberg, M. K., Ashman, K. & Martoglio, B. Identification of signal peptide peptidase, a presenilin-type aspartic protease. Science 296, 2215-2218 (2002).
13. Lemberg, M. K. & Martoglio, B. Requirements for signal peptide peptidase-catalyzed intramembrane proteolysis. Mol. Cell 10, 735-744 (2002).
14. Krawitz, P. et al. Differential localization and identification of a critical aspartate suggest non-redundant proteolytic functions of the presenilin in homologues SPPL2b and SPPL3. J. Biol. Chem. 280, 39515-39523 (2005).
15. Aggarwal, B. B. Signalling pathways of the TNF superfamily: A double-edged sword. Nature Rev. Immunol. 3, 745-756 (2003).
16. Weihofen, A. et al. Targeting presenilin-type aspartic protease signal peptide peptidase with γ-secretase inhibitors. J. Biol. Chem. 278, 16528-16533 (2003).
17. Watts, A. D., Hunt, N. H., Madigan, M. C. & Chaudhri, G. Soluble TNF-α receptors bind and neutralize over-expressed transmembrane TNF-α on macrophages, but do not inhibit its processing. J. Leukoc. Biol. 66, 1005-1013 (1999).
18. Banchereau, J. & Steinman, R. M. Dendritic cells and the control of immunity. Nature 392, 245-252 (1998).
19. Cella, M., Sallusto, F. & Lanzavecchia, A. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol. 9, 10-16 (1997).
20. Trinchieri, G., Pflanz, S. & Kastelein, R. A. The IL-12 family of heterodimeric cytokines: New players in the regulation of T cell responses. Immunity 19, 641-644 (2003).
21. Fujii, S., Liu, K., Smith, C., Bonito, A. J. & Steinman, R. M. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/ 86 costimulation. J. Exp. Med. 199, 1607-1618 (2004).
22. Ma, X. TNF-α and IL-12: A balancing act in macrophage functioning. Microbes Infect. 3, 121-129 (2001).
23. Cartstea, E. D., Hough, S., Wiederholt, K. & Welch, P. J. State-of-the-art modified RNAi compounds for therapeutics. IDrug 8, 642-647 (2005).
24. Yamada, Y., Kirillova, I., Peschon, J. J. & Fausto, N. Initiation of liver growth by tumor necrosis factor: Deficient liver regeneration in mice lacking type I tumor necrosis factor receptor, Proc. Natl Acad. Sci. USA 94, 1441-1446 (1997).
25. Steiner, H. et al. Glycine 384 is required for presenilin-1 function and is conserved in bacterial polytopic aspartyl proteases. Nature Cell Biol. 2, 848-851 (2000).
26. Moss, M. L. et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature 385, 733-736 (1997).
27. Peck, R., Brockhaus, M. & Frey, J. R. Cell surface tumor necrosis factor (TNF) accounts for monocyte- and lymphocyte-mediated killing of TNF-resistant target cells. Cell. Immunol. 122, 1-10 (1989).
28. Perez, C. et al. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 63, 251-258 (1990).
29. Grell, M. et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83, 793-802 (1995).
30. Eissner, G. et al. Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. J. Immunol. 164, 6193-6198 (2000).
31. Domonkos, A., Udvardy, A., Laszlo, L., Nagy, T. & Duda, E. Receptor-like properties of the 26 kDa transmembrane form of TNF. Eur. Cytokine Netw. 12, 411-419 (2001).
32. Hauben, E., Roncarolo, M. G., Nevo, U. & Schwartz, M. Beneficial autoimmunity in Type 1 diabetes mellitus. Trends Immunol. 26, 248-253 (2005).
33. Hammond, C. & Helenius, A. Quality control in the secretory pathway: retention of a misfolded viral membrane glycoprotein involves cycling between the ER, intermediate compartment, and Golgi apparatus. J. Cell Biol. 126, 41-52 (1994).
34. Wiltfang, J. et al. Improved electrophoretic separation and immunoblotting of β-amyloid (Aβ) peptides 1-40, 1-42, and 1-43. Electrophoresis 18, 527-532 (1997).